Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions

Hepatocellular carcinoma (HCC) is one of most common cancers that cause death in the world. Thermal ablation (TA) is an important alternative treatment method for HCC patients who are not appropriate for surgery or liver transplantation. Particularly for small and early HCCs, TA can be considered as the first-line curative treatment. However, local and distant recurrence rates are still high even though the TA equipment and technology develop rapidly. Immunotherapy is a novel systemic treatment method to enhance the anti-tumor immune response of HCC patients, which has the potential to reduce the tumor recurrence and metastasis. The combination of local TA and systemic immunotherapy for HCCs may be an ideal treatment for enhancing the efficacy of TA and controlling the recurrence. Herein we summarize the latest progress in TA, immunotherapy, and their combination for the treatment of patients with HCC and discuss the limitations and future research directions of the combined therapy.

Automated summary

Hepatocellular carcinoma is a common and deadly cancer, with thermal ablation being an important treatment option for patients who are not eligible for surgery or liver transplantation. Despite rapid advancements in TA technology, recurrence rates remain high, making immunotherapy a promising method to reduce tumor recurrence. The combination of local TA and systemic immunotherapy may be ideal for enhancing treatment efficacy and controlling recurrence.